{"pmid":32401064,"title":"CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.","text":["CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.","Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.","J Drug Target","Xiang, Xiaohong","Qian, Keli","Zhang, Zhen","Lin, Fengyun","Xie, Yang","Liu, Yang","Yang, Zongfa","32401064"],"abstract":["Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis."],"journal":"J Drug Target","authors":["Xiang, Xiaohong","Qian, Keli","Zhang, Zhen","Lin, Fengyun","Xie, Yang","Liu, Yang","Yang, Zongfa"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401064","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/1061186X.2020.1769637","keywords":["covid-19","crispr-cas","diagnostics","infectious diseases"],"locations":["Pneumonia"],"topics":["Diagnosis"],"weight":1,"_version_":1666714494696423424,"score":9.490897,"similar":[{"pmid":32366131,"title":"Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine.","text":["Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine.","Introduction: Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid that play a role in prokaryotic defense and form the basis of a genome editing technology that allows permanent alteration of genetic material. This methodology, known as CRISPR-Cas9, is poised to revolutionize molecular biology, but no literature yet exists on how these advances will affect hospitalists.Areas covered: These specialists in inpatient medicine care for a wide variety of hospitalized patients, including those with infectious disease, cancer, cardiovascular disease, autoimmune disease, hematologic disease, and a variety of other conditions that may soon be impacted by advances in gene-modifying technology provided by CRISPR-Cas9. A Literature search was performed using PubMed [1 December 2019-17 April 2020].Expert opinion: This paper reviews the remarkable diagnostic and therapeutic potential of the CRISPR-Cas9 platform and concludes with a look at ethical issues and technical hurdles pertaining to the implementation of permanent gene modification in the practice of Hospital Medicine.","Expert Rev Anti Infect Ther","McCarthy, Matthew W","32366131"],"abstract":["Introduction: Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of nucleic acid that play a role in prokaryotic defense and form the basis of a genome editing technology that allows permanent alteration of genetic material. This methodology, known as CRISPR-Cas9, is poised to revolutionize molecular biology, but no literature yet exists on how these advances will affect hospitalists.Areas covered: These specialists in inpatient medicine care for a wide variety of hospitalized patients, including those with infectious disease, cancer, cardiovascular disease, autoimmune disease, hematologic disease, and a variety of other conditions that may soon be impacted by advances in gene-modifying technology provided by CRISPR-Cas9. A Literature search was performed using PubMed [1 December 2019-17 April 2020].Expert opinion: This paper reviews the remarkable diagnostic and therapeutic potential of the CRISPR-Cas9 platform and concludes with a look at ethical issues and technical hurdles pertaining to the implementation of permanent gene modification in the practice of Hospital Medicine."],"journal":"Expert Rev Anti Infect Ther","authors":["McCarthy, Matthew W"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366131","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/14787210.2020.1761333","keywords":["crispr-cas9","sars-cov-2","hospitalist","nucleic acid","resistance"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496306249728,"score":469.34195},{"pmid":32349121,"title":"Massively multiplexed nucleic acid detection using Cas13.","text":["Massively multiplexed nucleic acid detection using Cas13.","The overwhelming majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanoliter droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of >4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with >/=10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. CARMEN's intrinsic multiplexing and throughput capabilities make it practical to scale, as miniaturization decreases reagent cost per test >300-fold. Scalable, highly-multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11).","Nature","Ackerman, Cheri M","Myhrvold, Cameron","Thakku, Sri Gowtham","Freije, Catherine A","Metsky, Hayden C","Yang, David K","Ye, Simon H","Boehm, Chloe K","Kosoko-Thoroddsen, Tinna-Solveig F","Kehe, Jared","Nguyen, Tien G","Carter, Amber","Kulesa, Anthony","Barnes, John R","Dugan, Vivien G","Hung, Deborah T","Blainey, Paul C","Sabeti, Pardis C","32349121"],"abstract":["The overwhelming majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanoliter droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of >4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with >/=10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. CARMEN's intrinsic multiplexing and throughput capabilities make it practical to scale, as miniaturization decreases reagent cost per test >300-fold. Scalable, highly-multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11)."],"journal":"Nature","authors":["Ackerman, Cheri M","Myhrvold, Cameron","Thakku, Sri Gowtham","Freije, Catherine A","Metsky, Hayden C","Yang, David K","Ye, Simon H","Boehm, Chloe K","Kosoko-Thoroddsen, Tinna-Solveig F","Kehe, Jared","Nguyen, Tien G","Carter, Amber","Kulesa, Anthony","Barnes, John R","Dugan, Vivien G","Hung, Deborah T","Blainey, Paul C","Sabeti, Pardis C"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349121","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41586-020-2279-8","topics":["Diagnosis"],"weight":1,"_version_":1666138495461097472,"score":399.23172},{"pmid":32376546,"pmcid":"PMC7086127","title":"[Laboratory testing techniques for SARS-CoV-2].","text":["[Laboratory testing techniques for SARS-CoV-2].","The ongoing epidemic of caused by the coronavirus SARS-CoV-2 starting in December 2019 poses a serious public health threat globally. The virus is highly infectious and transmitted mainly through droplets and contacts, and is associated with a high risk of pneumonia. A small number of patients may present with acute respiratory distress syndrome with severe respiratory complications, which can lead even to death. The selection of appropriate detection techniques and methods for accurate and rapid identification of pathogens therefore plays a key role in improving the diagnosis and treatment of the patients and containing the outbreak. In this review, the authors gives an overview of the virus laboratory detection technology, including virus isolation and culture, real-time fluorescent PCR, gene sequencing, serological antibody detection, and the gene editing technology based on CRISPR/Cas13 system. These techniques are expected to provide valuable assistance in controlling the epidemic and new ideas for future researches.","Nan Fang Yi Ke Da Xue Xue Bao","Qiu, Feng","Wang, Huijun","Zhang, Zikang","Cao, Longbin","Wang, Chenlong","Wu, Jingbiao","Du, Qingfeng","32376546"],"abstract":["The ongoing epidemic of caused by the coronavirus SARS-CoV-2 starting in December 2019 poses a serious public health threat globally. The virus is highly infectious and transmitted mainly through droplets and contacts, and is associated with a high risk of pneumonia. A small number of patients may present with acute respiratory distress syndrome with severe respiratory complications, which can lead even to death. The selection of appropriate detection techniques and methods for accurate and rapid identification of pathogens therefore plays a key role in improving the diagnosis and treatment of the patients and containing the outbreak. In this review, the authors gives an overview of the virus laboratory detection technology, including virus isolation and culture, real-time fluorescent PCR, gene sequencing, serological antibody detection, and the gene editing technology based on CRISPR/Cas13 system. These techniques are expected to provide valuable assistance in controlling the epidemic and new ideas for future researches."],"journal":"Nan Fang Yi Ke Da Xue Xue Bao","authors":["Qiu, Feng","Wang, Huijun","Zhang, Zikang","Cao, Longbin","Wang, Chenlong","Wu, Jingbiao","Du, Qingfeng"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376546","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.12122/j.issn.1673-4254.2020.02.04","keywords":["covid-19","pcr","sars-cov-2","gene editing"],"topics":["Diagnosis"],"weight":1,"_version_":1666597097457057792,"score":380.51053},{"pmid":32300245,"title":"CRISPR-Cas12-based detection of SARS-CoV-2.","text":["CRISPR-Cas12-based detection of SARS-CoV-2.","An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections. Our CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement.","Nat Biotechnol","Broughton, James P","Deng, Xianding","Yu, Guixia","Fasching, Clare L","Servellita, Venice","Singh, Jasmeet","Miao, Xin","Streithorst, Jessica A","Granados, Andrea","Sotomayor-Gonzalez, Alicia","Zorn, Kelsey","Gopez, Allan","Hsu, Elaine","Gu, Wei","Miller, Steve","Pan, Chao-Yang","Guevara, Hugo","Wadford, Debra A","Chen, Janice S","Chiu, Charles Y","32300245"],"abstract":["An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 infection, rapidly spread to produce a global pandemic. We report development of a rapid (<40 min), easy-to-implement and accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA extracts. We validated our method using contrived reference samples and clinical samples from patients in the United States, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections. Our CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement."],"journal":"Nat Biotechnol","authors":["Broughton, James P","Deng, Xianding","Yu, Guixia","Fasching, Clare L","Servellita, Venice","Singh, Jasmeet","Miao, Xin","Streithorst, Jessica A","Granados, Andrea","Sotomayor-Gonzalez, Alicia","Zorn, Kelsey","Gopez, Allan","Hsu, Elaine","Gu, Wei","Miller, Steve","Pan, Chao-Yang","Guevara, Hugo","Wadford, Debra A","Chen, Janice S","Chiu, Charles Y"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300245","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1038/s41587-020-0513-4","locations":["Wuhan","China","United States"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494779523076,"score":352.91153},{"pmid":32174267,"pmcid":"PMC7144283","title":"Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned.","text":["Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned.","Unexplained pneumonia (UP) caused by a novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) emerged in China in late December 2019 and has infected more than 9000 cases by 31 January 2020. Shanghai reported the first imported case of COVID-19 (Coronavirus Disease 2019) in 20 January 2020. A combinative approach of real-time RT-PCR, CRISPR-based assay and metagenomic next-generation sequencing (mNGS) were used to diagnose this unexplained pneumonia patient. Real-time RT-PCR and CRISPR-based assay both reported positive. This sample belonged to Betacoronavirus and shared a more than 99% nucleotide (nt) identity with the Wuhan SARS-CoV-2 isolates. We further compared pros and cons of common molecular diagnostics in UP. In this study, we illustrated the importance of combining molecular diagnostics to rule out common pathogens and performed mNGS to obtain unbiased potential pathogen result for the diagnosis of UP.","Emerg Microbes Infect","Ai, Jing-Wen","Zhang, Yi","Zhang, Hao-Cheng","Xu, Teng","Zhang, Wen-Hong","32174267"],"abstract":["Unexplained pneumonia (UP) caused by a novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) emerged in China in late December 2019 and has infected more than 9000 cases by 31 January 2020. Shanghai reported the first imported case of COVID-19 (Coronavirus Disease 2019) in 20 January 2020. A combinative approach of real-time RT-PCR, CRISPR-based assay and metagenomic next-generation sequencing (mNGS) were used to diagnose this unexplained pneumonia patient. Real-time RT-PCR and CRISPR-based assay both reported positive. This sample belonged to Betacoronavirus and shared a more than 99% nucleotide (nt) identity with the Wuhan SARS-CoV-2 isolates. We further compared pros and cons of common molecular diagnostics in UP. In this study, we illustrated the importance of combining molecular diagnostics to rule out common pathogens and performed mNGS to obtain unbiased potential pathogen result for the diagnosis of UP."],"journal":"Emerg Microbes Infect","authors":["Ai, Jing-Wen","Zhang, Yi","Zhang, Hao-Cheng","Xu, Teng","Zhang, Wen-Hong"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32174267","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1738905","keywords":["covid-19","sars-cov-2","unexplained pneumonia","diagnosis","molecular"],"locations":["China","Shanghai"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492589047809,"score":334.59036}]}